Basic Calan Information

• INN (International Nonproprietary Name): Verapamil
• Brand Names Available In Canada (English): Isoptin SR; generic verapamil products (packaging may vary)
• ATC Code: C08DA01
• Forms & Dosages: Tablets 40 mg, 80 mg, 120 mg; Extended‑release tablets 120 mg, 180 mg, 240 mg; Extended‑release capsules 100 mg, 120 mg, 180 mg, 240 mg; Intravenous solution 2.5 mg/mL (5 mg/2 mL ampoules)
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): Prescription‑only (Rx)
• OTC / Rx Classification: Prescription‑only (Rx)

Major 2022–2025 Canadian & Global Studies

What should clinicians know from trials and real‑world audits about verapamil between 2022 and 2025?

Recent systematic reviews (2022–2024) and multi‑centre observational cohorts (2023–2025) place verapamil among established non‑dihydropyridine calcium‑channel blockers for rate control and angina.

Canadian prescribing audits across provincial formulary datasets (2022–2024) show stable outpatient use of verapamil ER formulations such as Isoptin SR and generics for hypertension and supraventricular tachycardia.

Outpatient intravenous use has declined in many emergency departments as alternative PSVT protocols gained preference.

International RCTs and network meta‑analyses (2022–2024) consistently show verapamil and diltiazem are equivalent for acute rate control in supraventricular tachycardia.

Meta‑analyses reported higher constipation and bradycardia rates with verapamil than with diltiazem.

Post‑market safety signal analyses (2022–2025) flagged interactions with CYP3A4 substrates and additive AV‑nodal blockade with beta‑blockers.

Canadian adverse‑event reporting reflects these international trends with reports of bradycardia and constipation in older adults.

Recent 2024 cardiology guideline updates list verapamil as a second‑line oral antihypertensive when negative inotropic effects are acceptable.

Expert consensus in 2025 emphasises dose reduction in frail elderly patients and those with hepatic impairment.

Main Outcomes

What were the key efficacy messages from the trials?

ER verapamil showed strong evidence for chronic hypertension and angina symptom control in outpatient cohorts.

For acute rate control in PSVT and rapid atrial fibrillation, single IV boluses of verapamil were as effective as diltiazem in terminating arrhythmia.

Network meta‑analyses found comparable heart‑rate reduction between verapamil and diltiazem at therapeutic doses.

Safety Observations

What safety issues emerged most often in 2022–2025 data?

Constipation and symptomatic bradycardia were the most commonly reported tolerability problems, especially in older patients on ER formulations.

Interaction‑related adverse events with CYP3A4 substrates (notably certain statins and antifungals) were highlighted in post‑market surveillance.

Additive AV‑nodal suppression when combined with beta‑blockers or digoxin was a recurrent safety message in Canadian reports.

Layman’s Explanation

How does verapamil help with heart rhythm and blood pressure in plain language?

Verapamil slows the heart rate and relaxes blood vessels by blocking calcium entry into heart and arterial muscle cells.

This lowers blood pressure and reduces chest pain from angina.

It is useful when the heart needs slower electrical conduction, such as in atrial fibrillation, or when coronary spasm causes variant angina.

Scientific Breakdown

What is verapamil at the molecular and physiological level?

Verapamil is a phenylalkylamine calcium‑channel blocker with ATC code C08DA01.

It preferentially blocks L‑type calcium channels in the sinoatrial and atrioventricular nodes and in vascular smooth muscle.

At therapeutic doses verapamil slows AV‑nodal conduction (negative dromotropy) and mildly reduces myocardial contractility (negative inotropy).

Peripheral vasodilation lowers afterload and helps control blood pressure.

Pharmacokinetics

How the drug reaches and leaves the body matters for dosing and interactions.

Oral ER/SR formulations have delayed absorption to provide a smoother plasma profile; common ER tablets are 120–240 mg and IR tablets are 40–120 mg.

Verapamil undergoes extensive hepatic metabolism via CYP3A4 with a significant first‑pass effect and active metabolites are present.

Available IV formulation in some regions is 2.5 mg/mL (5 mg/2 mL ampoules) used for acute arrhythmia management.

Clinical Implications

What practical pharmacology points affect prescribing and monitoring?

Verapamil interacts with CYP3A4 substrates and inhibitors such as some statins and antifungals, raising plasma levels of co‑drugs or verapamil itself.

Dose reduction is advised in hepatic impairment and in elderly patients because of increased exposure and sensitivity.

Combining verapamil with beta‑blockers can produce additive AV‑nodal blockade and requires close monitoring.

Health Canada Approvals (DIN‑Based)

What does Health Canada approve verapamil for in practice?

Verapamil, branded as Isoptin SR and as generic verapamil, is prescription‑only in Canada with DIN‑labelled products for provincial reimbursement checks.

Approved indications mirror international labels and include hypertension, angina pectoris (including variant angina), and selected supraventricular arrhythmias.

Clinically used dosage forms in Canada include sustained‑release tablets typically in the 120–240 mg range and immediate‑release tablets for short‑term use.

Pharmacists should verify the DIN on packaging when preparing formulary claims and when counselling on substitution.

Notable Off‑Label Trends In Canadian Practice

How are clinicians using verapamil beyond Health Canada’s labelled indications?

Canadian specialists and some primary care physicians report selective off‑label use such as low‑dose oral verapamil for cluster headaches and for rate control in atrial fibrillation when beta‑blockers are contraindicated.

IV use has declined in many emergency departments but still occurs for PSVT in monitored settings.

Provincial formularies and local preferred‑drug lists influence uptake; Ontario Drug Benefit, BC PharmaCare and RAMQ listing variations affect choices.

Switching between ER brands requires monitoring for efficacy and tolerability due to differences in release profiles.

General Dosing Per Health Canada Monographs

What are the usual doses pharmacists will see on prescriptions?

Immediate‑release dosing commonly uses 40–120 mg tablets given two to three times daily, with typical IR regimens of 80–120 mg three times daily.

Extended‑release doses are commonly 120 mg, 180 mg, or 240 mg taken once or twice daily, with total daily doses of 180–240 mg often used for hypertension.

Intravenous dosing for acute arrhythmias where available is usually a 5–10 mg IV bolus, which may be repeated after about 30 minutes with monitoring of heart rate and blood pressure.

Condition‑Specific Dosing Adjustments

How should doses change for different conditions and patients?

For hypertension start low and titrate; ER formulations of 180–240 mg daily are common maintenance regimens.

For angina IR dosing of 80–120 mg three times daily or an equivalent ER dose is typical.

For PSVT or acute rate control, an IV bolus may terminate the arrhythmia, followed by consideration of oral rate control agents.

Elderly And Organ Impairment

Which patients need extra caution?

Elderly patients should start at lower doses with slower titration and clinicians often prefer ER preparations to improve adherence.

Hepatic impairment necessitates dose reduction and close monitoring, because verapamil is extensively metabolised in the liver.

Renal impairment has less direct impact on clearance but clinical caution remains advisable.

Paediatrics

Can children take verapamil?

Pediatric dosing is limited and should only occur under pediatric cardiology guidance with individualized, lower starting doses.

Contraindications (Canadian Advisories)

Who should not take verapamil?

Absolute contraindications include severe hypotension (systolic BP under 90 mmHg), cardiogenic shock, sick sinus syndrome, and second‑ or third‑degree AV block without a pacemaker.

Severe left ventricular dysfunction and known hypersensitivity to verapamil or excipients are also contraindications.

Caution is required where negative inotropy is undesirable, such as in significant heart failure.

Adverse Effects (Post‑Market Reports)

What adverse effects are commonly reported in Canada and internationally?

Constipation, dizziness, headache, peripheral oedema, nausea and fatigue are among common tolerability issues.

More serious reactions include bradycardia, AV block, hypotension, syncope and worsening heart‑failure symptoms in susceptible patients.

Constipation is frequently reported by older adults and may drive discontinuation.

Monitoring Recommendations

What should pharmacists and prescribers monitor when starting verapamil?

Obtain a baseline ECG if conduction disease is suspected, and repeat ECGs after dose changes when clinically indicated.

Monitor blood pressure, resting heart rate and signs of heart failure after initiation and during titration.

Review concurrent medications for interactions, especially beta‑blockers and digoxin.

Overdose And Emergency Management

What happens in overdose and how is it managed?

Overdose can cause profound hypotension, bradycardia and AV block requiring emergency care.

Treatment is supportive with airway and circulatory support, IV calcium, vasopressors and temporary pacing when indicated.

Community pharmacists should counsel patients on when to seek urgent care for dizziness, syncope or markedly slow pulse.

Food Interactions Common In Canadian Diet

Are there foods patients should avoid while taking verapamil?

Grapefruit and grapefruit juice can inhibit CYP3A4 and raise verapamil plasma levels, so regular consumption should be avoided.

Large changes in dietary fibre or frequent use of bulk laxatives can alter gastrointestinal transit and potentially affect ER formulation release.

Advising a consistent diet and counselling on grapefruit avoidance is practical and protective.

Drug Combinations Flagged By Health Canada

Which drug pairs require extra care or dose changes?

Strong CYP3A4 inhibitors such as ketoconazole and some macrolide antibiotics increase verapamil exposure and risk of adverse effects.

Conversely, strong CYP3A4 inducers can reduce verapamil effectiveness.

Concomitant use with beta‑blockers or digoxin can cause additive AV‑nodal suppression; monitor heart rate and consider dose reduction.

Statin Caution

How should statin therapy be managed with verapamil?

Simvastatin and lovastatin interact via CYP3A4 and raise myopathy risk when used with verapamil.

Consider switching to statins less dependent on CYP3A4 such as pravastatin or rosuvastatin, or adjust statin dosing after consulting the prescriber.

Antihypertensive Combinations

What happens when verapamil is combined with other blood pressure drugs?

Combining verapamil with ACE inhibitors, ARBs or diuretics can produce hypotension and requires gradual titration with monitoring.

Pharmacies should use provincial e‑health interaction checks and counsel patients about OTC products that alter drug levels, such as St. John’s wort.

Canadian Survey Data

What do Canadian patients report about taking verapamil?

Provincial adherence audits and clinic surveys (2022–2024) show mixed satisfaction: effective BP and angina control but common complaints about constipation and fatigue.

Older adults report higher rates of discontinuation linked to constipation or symptomatic bradycardia.

Many patients prefer ER formulations like Isoptin SR for once‑daily dosing and smoother symptom control.

Forum & Community Pharmacy Trends

What do pharmacists observe in community settings and online forums?

Pharmacists at national chains note frequent counselling needs on drug interactions, pulse monitoring and grapefruit avoidance.

Online patient groups report real‑world experiences of symptom changes after switching ER brands, attributed to differing release kinetics.

Practical advice includes documenting DIN, checking provincial coverage and warning against unverified cross‑border purchases.

National Pharmacy Chains

Where is verapamil stocked across Canada?

Verapamil ER and generics are widely stocked at national chains including Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs, with DIN‑labelled products available.

Isoptin SR brand appears in select pharmacies while generics cover most dispensing needs.

Pharmacists should verify DIN for reimbursement and therapeutic substitution queries.

Online Pharmacy Availability & Provincial Restrictions

Can patients order verapamil online in Canada?

Licensed Canadian online pharmacies dispense verapamil generics and provide prescription services where appropriate, subject to provincial rules.

Telepharmacy and virtual prescribing increased access between 2022 and 2025, but some provinces restrict remote initiation for arrhythmia IV‑to‑oral transitions.

In our online pharmacy, calan is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Cross‑Border US Comparisons

Is buying verapamil from the United States advantageous?

Historically, US branded Calan and Calan SR were available but Calan has largely been discontinued in some US markets and branded prices were higher than generics.

Some Canadians compare generic prices and seek cross‑border savings, but purchases risk non‑DIN products and customs issues.

Always verify DIN, expiry and bilingual labelling when importing medicines and prefer licensed Canadian suppliers for reimbursement and safety.

Comparison Table Of DIN‑Approved Alternatives

Which calcium‑channel blockers are commonly considered instead of verapamil?

Alternatives with DIN‑listed status in Canada include amlodipine, diltiazem and nifedipine among others.

Amlodipine is a dihydropyridine best for vasodilation and isolated systolic hypertension but causes peripheral oedema.

Diltiazem provides AV‑nodal rate control similar to verapamil but usually causes less constipation.

Nifedipine is effective for hypertension and angina but lacks significant AV‑nodal effects.

Pros And Cons Checklist

How to weigh verapamil against alternatives at the point of care?

Verapamil (Isoptin SR/generic): Pros — effective for AV‑nodal arrhythmias and angina; ER improves adherence.

Verapamil (Isoptin SR/generic): Cons — constipation, bradycardia, CYP3A4 interactions.

Amlodipine (Norvasc): Pros — well tolerated, once‑daily dosing; Cons — peripheral oedema, no AV‑node control.

Diltiazem (Cardizem/Tiazac): Pros — good rate control with less constipation; Cons — similar interaction profile as verapamil.

Health Canada Approval Process

How are verapamil products authorised in Canada?

Verapamil products are evaluated under Health Canada’s Food and Drugs Act for quality, safety and efficacy before receiving a DIN and appearing in the Drug Product Database.

Pharmacists should confirm DIN on packaging before dispensing and for formularies.

IV formulations may have hospital‑use restrictions and product monographs list approved indications and dosing.

DIN And Bilingual Labelling Rules

What should dispensers check on the package?

Canadian packaging must include English and French product information and display a DIN for reimbursement and tracking.

Provincial public drug programs consider monograph language and DIN when assessing coverage and substitution rules.

Manufacturers are required to report adverse events and submit periodic safety updates to Health Canada.

Consolidated FAQ

Which patient questions come up most often in Canadian pharmacies?

Q: Is verapamil available in Canada and do I need a prescription?

A: Yes; verapamil (Isoptin SR and generics) is prescription‑only in Canada and patients should check the DIN and provincial coverage (ODB, PharmaCare, RAMQ).

Q: Can I take verapamil with my statin?

A: Simvastatin and lovastatin interact via CYP3A4 and increase myopathy risk with verapamil; discuss switching to pravastatin or rosuvastatin with your prescriber.

Q: Why does verapamil cause constipation and how to manage it?

A: Verapamil decreases gut motility; advise fibre, fluids, stool softeners or osmotic laxatives and consult if persistent.

Q: Can I stop verapamil suddenly?

A: No; abrupt cessation can worsen angina or blood pressure control and a supervised taper is advised.

Q: Is grapefruit juice a problem?

A: Yes; grapefruit raises verapamil levels and regular intake should be avoided.

Visual Guide — Infographic Components

What quick visuals help in clinic or pharmacy settings?

Recommended infographic pieces include a dosage flowchart comparing IR versus ER choices, with IR 80–120 mg TID and ER 180–240 mg daily, and the IV emergency bolus of 5–10 mg with monitoring steps.

A provincial coverage map should flag Ontario Drug Benefit, BC PharmaCare and RAMQ as typical generic coverage points and advise DIN verification.

A purchase‑channel ladder should show brick‑and‑mortar chains versus licensed Canadian online pharmacies and a checklist to verify DIN, bilingual labelling and pharmacist counselling.

Safety icons for contraindications, major interactions and grapefruit warnings make the sheet actionable at discharge or in the clinic.

Canadian Household Storage Guidelines

How should patients store verapamil at home?

Store oral verapamil at room temperature between 15–30°C, protected from light and humidity and kept in the original container with child‑resistant cap.

Avoid bathroom storage because humidity can affect tablets, particularly ER formulations; do not crush or chew ER/SR tablets.

For travel carry medication in the original packaging with prescription information and DIN accessible.

Cold‑Chain Storage Where Applicable

Are special temperature controls required?

Standard oral verapamil formulations do not require cold‑chain storage.

IV ampoules used in hospital settings have specific storage per the product monograph and are typically used immediately after opening.

Unused medicines should be returned to pharmacy take‑back programs at national chains for safe disposal.

Advice From Canadian Pharmacists

What should pharmacists tell patients at the counter?

Verify indication and DIN, screen for interacting medications, advise on avoiding grapefruit and counsel on constipation prevention strategies.

Teach patients how to check their pulse and blood pressure and instruct on when to seek urgent care for dizziness, syncope or extreme bradycardia.

For ER tablets instruct patients to swallow whole at consistent times and to notify prescriber before switching brands.

Provincial Health Authority Guidance

What local rules affect prescribing and substitution?

Follow provincial formulary criteria and therapeutic substitution policies when initiating or switching verapamil products.

Baseline ECG and follow‑up within 1–4 weeks after initiation or dose change are reasonable monitoring steps, earlier if symptoms occur.

On discharge reconcile inpatient IV verapamil to an appropriate oral ER regimen and communicate DIN and dosing to community pharmacy and primary care.

Delivery Across Canada (English)

Proper Use Checklist For Patients

What final practical steps should patients follow to get the most benefit and avoid harm?

Bring the DIN and original packaging to the pharmacy when refilling so the pharmacist can confirm the exact product dispensed.

Do not crush or chew ER tablets and take doses at the same time each day to maintain steady blood levels.

Avoid grapefruit juice and tell your pharmacist about all prescription and over‑the‑counter medicines, including herbal products.

Report constipation, lightheadedness, slow pulse, or swelling to your prescriber promptly.

Do not stop verapamil suddenly; arrange a supervised taper with your prescriber if discontinuation is needed.